Cutrer F Michael, Charles Andrew
Mayo Clinic, Rochester, MN 55902, USA.
Headache. 2008 Oct;48(9):1411-4. doi: 10.1111/j.1526-4610.2008.01277.x.
There is accumulating evidence of a neurogenic basis of migraine. This evidence arises from both the clinical and experimental domains. Many of the well known clinical features of migraine attacks including the prodrome are not explained by changes in vascular caliber. Despite the fact that ergotamines and triptans are vasoactive does not provide substantive proof that vasoconstriction is their most important mechanism of action. Several effective treatments for migraine, both old and new, do not affect vascular caliber. Experimental evidence from investigation of both the aura and headache phases of migraine clearly supports a neural basis of migraine. All genes thus far conclusively associated with hemiplegic migraine code for neural proteins.
越来越多的证据表明偏头痛存在神经源性基础。这一证据来自临床和实验领域。偏头痛发作的许多著名临床特征，包括前驱症状，无法用血管管径的变化来解释。尽管麦角胺和曲坦类药物具有血管活性，但这并不能提供实质性证据证明血管收缩是它们最重要的作用机制。几种治疗偏头痛的新旧有效方法都不会影响血管管径。对偏头痛先兆期和头痛期的研究获得的实验证据明确支持偏头痛的神经基础。迄今为止，所有与偏瘫性偏头痛明确相关的基因都是编码神经蛋白的。
